White House regulatory reform agenda
This article was originally published in The Gray Sheet
Executive Summary
Office of Management and Budget is taking nominations for regs and guidance documents that impose "especially large burdens on small businesses and other small entities without an adequate benefit justification" for review. Issued March 18, 1OMB's draft report to Congress on the costs and benefits of federal regulations carries a 60-day comment period. HHS Secretary Thompson recently established a department-wide advisory panel on regulatory reform, set to meet March 20-21 in Phoenix. That panel is independently seeking comments on burdensome regulations (2"The Gray Sheet" March 18, 2002, p. 14). OMB also states that a "scientific advisory panel" including health and medical science experts will meet twice a year to evaluate Office of Information and Regulatory Affairs activities...
You may also be interested in...
Blood Safety Authority Shift To CDRH Opposed By Blood Centers
Legislation shifting responsibility for the regulation of blood safety screening tests from FDA's Center for Biologics Evaluation and Research to the device center puts an enormous burden on blood organizations, according to America's Blood Centers (ABC)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.